International Generic Drug Regulators Programme (IGDRP)
The European Medicines Agency (EMA) participates in the International Generic Drug Regulators Programme (IGDRP), which promotes regulatory collaboration and convergence to achieve greater regulatory efficiency and address challenges posed by globalised production and distribution chains and increasingly sophisticated generic products.
Merger of IGDRP and the International Pharmaceutical Regulators Forum (IPRF) (new)
IGDRP and IPRF have merged to form a single forum for international regulators to exchange practice and develop opportunities for cooperation, the International Pharmaceutical Regulators Programme (IPRP).
This new forum was launched on 1 January 2018. IPRP expects to launch a new website in the second quarter of 2018. For more information, see the press release by IGDPR.
Collaboration through the IGDRP aims to:
- ensure timely patient access to high quality generic medicines;
- increase regulatory efficiency through the sharing of assessments and quality and safety information;
- enhance global regulatory harmonisation of assessments of generic medicines.
For participating agencies and organisations, see IGDRP: About us.
From January 2015, EMA has been running a pilot for sharing its assessments of generic medicines with participating regulatory agencies outside the European Union (EU), as part of the IGDRP information-sharing iniative.
The objective is to provide:
- a more efficient and consistent review process;
- reducing regulatory burden;
- facilitating the similar timing of market authorisations in different regions of the world.
For more information and eligibility criteria, see: